Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Jonas

Showing results (801-810 of 828) with videos related to

Pageof 83
Sort By:
The New England Journal of Medicine|October 7, 1993
A comparison of the perioperative neurologic effects of hypothermic circulatory arrest versus low-flow cardiopulmonary bypass in infant heart surgeryJ W Newburger, R A Jonas, G Wernovsky, et al.
World Journal for Pediatric & Congenital Heart Surgery|March 27, 2014
Linking the congenital heart surgery databases of the Society of Thoracic Surgeons and the Congenital Heart Surgeons' Society: part 1--rationale and methodologyJeffrey P Jacobs, Sara K Pasquali, Erle Austin, et al.
Blood|September 24, 2024
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohortMendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, et al.
American Journal of Hematology|February 12, 2024
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemiaKeith W Pratz, Brian A Jonas, Vinod Pullarkat, et al.
In Vivo (Athens, Greece)|June 23, 2022
Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AMLDaniel H Albert, Neal C Goodwin, Angela M Davies, et al.
Haematologica|April 2, 2026
Treatment of <i>TP53</i>-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclaxMendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, et al.
World Journal for Pediatric & Congenital Heart Surgery|June 28, 2018
History of the World Society for Pediatric and Congenital Heart Surgery: The First DecadeJeffrey P Jacobs, Christo I Tchervenkov, Giovanni Stellin, et al.
Blood Advances|February 1, 2023
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AMLStéphane de Botton, Pierre Fenaux, Karen Yee, et al.
Blood|October 20, 2022
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trialNaval G Daver, Monique Dail, Jacqueline S Garcia, et al.
The Annals of Thoracic Surgery|August 7, 2015
The Society of Thoracic Surgeons Congenital Heart Surgery Database Mortality Risk Model: Part 2-Clinical ApplicationJeffrey P Jacobs, Sean M O'Brien, Sara K Pasquali, et al.
Pageof 83

Showing results (801-810 of 828) with videos related to

Sort By:
Pageof 83
The New England Journal of Medicine|October 7, 1993
A comparison of the perioperative neurologic effects of hypothermic circulatory arrest versus low-flow cardiopulmonary bypass in infant heart surgeryJ W Newburger, R A Jonas, G Wernovsky, et al.
World Journal for Pediatric & Congenital Heart Surgery|March 27, 2014
Linking the congenital heart surgery databases of the Society of Thoracic Surgeons and the Congenital Heart Surgeons' Society: part 1--rationale and methodologyJeffrey P Jacobs, Sara K Pasquali, Erle Austin, et al.
Blood|September 24, 2024
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohortMendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, et al.
American Journal of Hematology|February 12, 2024
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemiaKeith W Pratz, Brian A Jonas, Vinod Pullarkat, et al.
In Vivo (Athens, Greece)|June 23, 2022
Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AMLDaniel H Albert, Neal C Goodwin, Angela M Davies, et al.
Haematologica|April 2, 2026
Treatment of <i>TP53</i>-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclaxMendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, et al.
World Journal for Pediatric & Congenital Heart Surgery|June 28, 2018
History of the World Society for Pediatric and Congenital Heart Surgery: The First DecadeJeffrey P Jacobs, Christo I Tchervenkov, Giovanni Stellin, et al.
Blood Advances|February 1, 2023
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AMLStéphane de Botton, Pierre Fenaux, Karen Yee, et al.
Blood|October 20, 2022
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trialNaval G Daver, Monique Dail, Jacqueline S Garcia, et al.
The Annals of Thoracic Surgery|August 7, 2015
The Society of Thoracic Surgeons Congenital Heart Surgery Database Mortality Risk Model: Part 2-Clinical ApplicationJeffrey P Jacobs, Sean M O'Brien, Sara K Pasquali, et al.
Pageof 83